110
Citations
64
Journals
2015
First Cited
2022
Last Cited

Articles citing This Document (Page 1 of 3)

ArticleJournalYear
Systematic Review on the Use of Biosimilars of Trastuzumab in HER2+ Breast Cancer2022
Non-Medical Switching in Dermatology: Cost-Conscious Policy or an Affront to Patient Safety?
Introductory Chapter: Biosimilars - A Regulatory and Clinical Perspective
Biosimilars in der pädiatrischen RheumatologieSpringer Reference Medizin2022
Comparison of Three Complementary Analytical Techniques for the Evaluation of the Biosimilar Comparability of a Monoclonal Antibody and an Fc-Fusion Protein.Frontiers in Chemistry2021
Evaluation of physicochemical and functional similarity of a new CHO derived anti-EGFR antibody P-mAb to its reference medicinal product.Artificial Cells, Nanomedicine and Biotechnology2022
Biosimilars for Psoriasis2021
Interchangeability Study Design and AnalysisAAPS Advances in the Pharmaceutical Sciences Series2018
Insights on the use of biosimilars in the treatment of inflammatory bowel diseaseWorld Journal of Gastroenterology2017
BIOSIMILARS IN RHEUMATOLOGYNauchno-Prakticheskaya Revmatologiya2017
Immunogenicity Assessment of Biosimilars: A Multidisciplinary PerspectiveAAPS Advances in the Pharmaceutical Sciences Series2018
Statistical Considerations for Demonstration of Analytical SimilarityAAPS Advances in the Pharmaceutical Sciences Series2018
Role of Pharmacokinetics: Pharmacodynamics in Biosimilar Assessment2016
A Randomized Phase 1 Pharmacokinetic Study Comparing the Potential Biosimilar LRG201902 With Liraglutide (Victoza) in Healthy Male SubjectsFrontiers in Pharmacology2020
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumabJournal of Cancer Research and Clinical Oncology2021
Pharmacokinetic equivalence of CT-P17 to high-concentration (100 mg/ml) reference adalimumab: A randomized phase I study in healthy subjectsClinical and Translational Science2021
A Phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX02 to reference CN- and EU-sourced trastuzumab in healthy subjectsCancer Chemotherapy and Pharmacology2021
The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory DiseasesDrugs2020
Mobilization of Hematopoietic Stem Cells into Peripheral Blood for Autologous Transplantation Seems Less Efficacious in Poor Mobilizers with the Use of a Biosimilar of Filgrastim and Plerixafor: A Retrospective Comparative AnalysisOncology and Therapy2020
Biosimilar Drug Development2020
Biologic Drug Quality Assurance to Optimize HER2 + Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3Targeted Oncology2020
Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory DocumentsBioDrugs2020
Anti-tumor necrosis factor biosimilars and intended copies in rheumatology: Perspective from the Asia Pacific regionInternational Journal of Rheumatic Diseases2019
Regulation of biosimilar medicines and current perspectives on interchangeability and policyEuropean Journal of Clinical Pharmacology2019
Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III TrialBioDrugs2019
Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropeniaAnnals of Hematology2019
Adalimumab Biosimilars in Europe: An Overview of the Clinical EvidenceBioDrugs2019
Barriers towards effective pharmacovigilance systems of biosimilars in rheumatology: A Latin American surveyPharmacoepidemiology and Drug Safety2019
Genetic engineering approaches to improve posttranslational modification of biopharmaceuticals in different production platformsBiotechnology and Bioengineering2019
Biological Characterization of SB3, a Trastuzumab Biosimilar, and the Influence of Changes in Reference Product Characteristics on the Similarity AssessmentBioDrugs2019
Era of biosimilars in rheumatology: reshaping the healthcare environmentRMD Open2019
Aptamers as quality control tool for production, storage and biosimilarity of the anti-CD20 biopharmaceutical rituximabScientific Reports2019
GP2017, an adalimumab biosimilar: pharmacokinetic similarity to its reference medicine and pharmacokinetics comparison of different administration methodsExpert Opinion on Biological Therapy2019
Sensitivity of Pegfilgrastim Pharmacokinetic and Pharmacodynamic Parameters to Product Differences in Similarity StudiesAAPS Journal2019
Bioengineering of rFVIIa Biopharmaceutical and Structure Characterization for Biosimilarity AssessmentBioengineering2018
Biosimilars are coming: ready or notInternal Medicine Journal2018
A comparative pharmacokinetic study of DRL_BZ, a candidate biosimilar of bevacizumab, with Avastin (EU and US) in healthy male subjectsBritish Journal of Clinical Pharmacology2018
Global Acceptance of Biosimilars: Importance of Regulatory Consistency, Education, and TrustOncologist2018
Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature ReviewBioDrugs2018
Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future DirectionDrug Safety2018
Risk-Based Comparability Assessment for Monoclonal Antibodies During Drug Development: A Clinical Pharmacology PerspectiveAAPS Journal2018
Development of New Formulations of Biologics: Expectations, Immunogenicity, and Safety for Subcutaneous TrastuzumabPharmaceutical Medicine2018
Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA studyRMD Open2018
Sample Size for Multiple Hypothesis Testing in Biosimilar DevelopmentStatistics in Biopharmaceutical Research2018
The Role of Rituximab in Chronic Lymphocytic Leukemia Treatment and the Potential Utility of BiosimilarsOncologist2018
Inappropriate claims from non-equivalent medications in osteoarthritis: a position paper endorsed by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO)Aging Clinical and Experimental Research2018
Consensus-based recommendations for the use of biosimilars to treat rheumatological diseasesAnnals of the Rheumatic Diseases2018
Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid ArthritisArthritis and Rheumatology2018
Variability of intended copies for etanercept (Enbrel®): Data on multiple batches of seven productsMAbs2018
Biosimilar Drugs for Psoriasis: Principles, Present, and Near FutureDermatology and Therapy2018